Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and oral vinorelbine in HR+ advanced breast cancer
NCT03939871Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fulvestrant and vinorelbine in Hormone-Receptor-Positive Breast Cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 1.5 years. Status: unknown.
02
Drugs
fulvestrantvinorelbine
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03939871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939871.